Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease
Authors
Keywords
-
Journal
Expert Opinion on Drug Metabolism & Toxicology
Volume 10, Issue 6, Pages 839-857
Publisher
Informa Healthcare
Online
2014-03-26
DOI
10.1517/17425255.2014.902444
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and Efficacy of Metformin in Patients With Type 2 Diabetes Mellitus and Chronic Hepatitis C
- (2014) Kira Harris et al. ANNALS OF PHARMACOTHERAPY
- Canagliflozin, a Novel SGLT2 Inhibitor for Treatment of Type 2 Diabetes
- (2014) Stefanie C. Nigro et al. ANNALS OF PHARMACOTHERAPY
- Renal failure in chronic liver disease and the hepatorenal syndrome
- (2014) Brijesh Srivastava et al. BRITISH JOURNAL OF HOSPITAL MEDICINE
- Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
- (2014) André J. Scheen CLINICAL PHARMACOKINETICS
- Quels bénéfices antitumoraux attendre de la metformine ?
- (2013) Emmanuel Beck et al. ANNALES D ENDOCRINOLOGIE
- The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes
- (2013) Diethelm Tschöpe et al. Cardiovascular Diabetology
- The Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Ipragliflozin, a Novel Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor
- (2013) Wenhui Zhang et al. CLINICAL DRUG INVESTIGATION
- Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2
- (2013) Sreeneeranj Kasichayanula et al. CLINICAL PHARMACOKINETICS
- Metformin revisited: A critical review of the benefit–risk balance in at-risk patients with type 2 diabetes
- (2013) A.J. Scheen et al. DIABETES & METABOLISM
- Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
- (2013) Mei Zhang et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease
- (2013) André J Scheen Expert Opinion on Drug Metabolism & Toxicology
- Canagliflozin, an inhibitor of sodium–glucose cotransporter 2, for the treatment of type 2 diabetes mellitus
- (2013) Elizabeth M Lamos et al. Expert Opinion on Drug Metabolism & Toxicology
- Mitiglinide for type 2 diabetes treatment
- (2013) Haley M Phillippe et al. EXPERT OPINION ON PHARMACOTHERAPY
- Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus
- (2013) Thomas Forst et al. EXPERT OPINION ON PHARMACOTHERAPY
- Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease
- (2013) Yasuji Arase et al. HEPATOLOGY RESEARCH
- Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: Pooled analysis of data from three placebo-controlled phase III trials
- (2013) Stefano Del Prato et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Dipeptidyl peptidase-4: A key player in chronic liver disease
- (2013) Minoru Itou WORLD JOURNAL OF GASTROENTEROLOGY
- Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial
- (2013) Matthew J Armstrong et al. BMJ Open
- Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
- (2013) Samuel S. Engel et al. Diabetes Therapy
- Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program
- (2012) M. J. Armstrong et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Pharmacokinetics of linagliptin in subjects with hepatic impairment
- (2012) Ulrike Graefe-Mody et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin
- (2012) Yan-Ling He CLINICAL PHARMACOKINETICS
- Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors
- (2012) Larry K. Golightly et al. CLINICAL PHARMACOKINETICS
- Mechanisms Involved in the Protective Effects of Metformin Against Nonalcoholic Fatty Liver Disease
- (2012) V. J. Barbero-Becerra et al. CURRENT MEDICINAL CHEMISTRY
- Dorothy Hodgkin Lecture 2012* Non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management
- (2012) C. D. Byrne DIABETIC MEDICINE
- Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETOLOGIA
- Dapagliflozin
- (2012) Greg L. Plosker DRUGS
- Repaglinide
- (2012) Lesley J. Scott DRUGS
- GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations
- (2012) Maria J Jespersen et al. Expert Opinion on Drug Metabolism & Toxicology
- Drug-induced hypoglycaemia in type 2 diabetes
- (2012) Berit Inkster et al. Expert Opinion On Drug Safety
- Saxagliptin overview: special focus on safety and adverse effects
- (2012) Shamsa Ali et al. Expert Opinion On Drug Safety
- Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin
- (2012) Stephen A. Harrison et al. HEPATOLOGY
- Liver and diabetes. A vicious circle
- (2012) Paola Loria et al. HEPATOLOGY RESEARCH
- Managing Diabetes in Patients with Chronic Liver Disease
- (2012) Roaid Khan et al. POSTGRADUATE MEDICINE
- The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
- (2012) Takamasa Ohki et al. TheScientificWorldJOURNAL
- Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin
- (2011) David W. Boulton et al. CLINICAL PHARMACOKINETICS
- Clinical Pharmacokinetics of Metformin
- (2011) Garry G. Graham et al. CLINICAL PHARMACOKINETICS
- Influence of Hepatic Impairment on the Pharmacokinetics and Safety Profile of Dapagliflozin: An Open-Label, Parallel-Group, Single-Dose Study
- (2011) Sreeneeranj Kasichayanula et al. CLINICAL THERAPEUTICS
- The Role of Metformin in the Management of NAFLD
- (2011) Angela Mazza et al. Experimental Diabetes Research
- Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation)
- (2011) André J Scheen Expert Opinion on Drug Metabolism & Toxicology
- A review of gliptins in 2011
- (2011) André J Scheen EXPERT OPINION ON PHARMACOTHERAPY
- Sitagliptin as a Novel Treatment Agent for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus
- (2011) Tomoyuki Iwasaki et al. HEPATO-GASTROENTEROLOGY
- Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus
- (2011) Yasuji Arase et al. HEPATOLOGY RESEARCH
- A Case of Drug-induced Hepatic Injury Associated with Sitagliptin
- (2011) Megumi Toyoda-Akui et al. INTERNAL MEDICINE
- Impact of Metformin on the Prognosis of Cirrhosis Induced by Viral Hepatitis C in Diabetic Patients
- (2011) Gisèle Nkontchou et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Impact of liver diseases on the development of type 2 diabetes mellitus
- (2011) Po-Shiuan Hsieh WORLD JOURNAL OF GASTROENTEROLOGY
- The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis
- (2011) Lisa B. Van Wagner et al. Therapeutic Advances in Gastroenterology
- Pioglitazone in the treatment of NASH: the role of adiponectin
- (2010) A. Gastaldelli et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Elevated Hepatic Enzymes Potentially Associated with Sitagliptin
- (2010) Benjamin N Gross et al. ANNALS OF PHARMACOTHERAPY
- Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide
- (2010) Anne Flint et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacokinetics of dipeptidylpeptidase-4 inhibitors
- (2010) A. J. Scheen DIABETES OBESITY & METABOLISM
- An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials
- (2010) M. Ligueros-Saylan et al. DIABETES OBESITY & METABOLISM
- Role of Continuous Subcutaneous Insulin Infusion (Insulin Pump) in Reducing Blood Glucose in Four Patients with Type 2 Diabetes and Cirrhosis: A Case Series
- (2010) Johny J. Kannampilly Diabetes Technology & Therapeutics
- Metabolism and Excretion of the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide in Healthy Male Subjects and Its In Vitro Degradation by Dipeptidyl Peptidase IV and Neutral Endopeptidase
- (2010) M. Malm-Erjefalt et al. DRUG METABOLISM AND DISPOSITION
- Lactic Acidosis Induced by Metformin
- (2010) Jean-Daniel Lalau DRUG SAFETY
- Clarifying metformin's role and risks in liver dysfunction
- (2010) Carolyn C. Brackett JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION
- Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease
- (2010) Valter Donadon et al. LIVER INTERNATIONAL
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selection and Dosing of Medications for Management of Diabetes in Patients with Advanced Kidney Disease
- (2010) James B. Reilly et al. SEMINARS IN DIALYSIS
- Thiazolidinediones and the liver in humans
- (2009) Hannele Yki-Järvinen CURRENT OPINION IN LIPIDOLOGY
- Liver Safety in Patients with Type 2 Diabetes Treated with Pioglitazone
- (2009) Keith G. Tolman et al. DRUG SAFETY
- Pioglitazone improves virological response to peginterferon α-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance
- (2009) Mahmoud Khattab et al. LIVER INTERNATIONAL
- Liver cirrhosis and diabetes: Risk factors, pathophysiology, clinical implications and management
- (2009) Diego Garcia-Compean et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction
- (2008) Roger K. Verbeeck EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Different Effects ofSLCO1B1Polymorphism on the Pharmacokinetics and Pharmacodynamics of Repaglinide and Nateglinide
- (2008) Annikka Kalliokoski et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide
- (2008) Annikka Kalliokoski et al. Pharmacogenetics and Genomics
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started